Perianal Fistulas in Crohn’s Disease Patients
Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601
The phase III ADMIRE-CD trials proved that a single administration of Cx601 (the suspension of allogeneic expanded adipose-derived stem cells) and standard therapy was significantly more likely to heal fistulas in patienst who suffer from perianal fistulizing Crohn’s disease compared to standard therapy and placebo. This therapy led to remission in 56 % pacients vs. 39 % patienst with placebo, and maintained long-term (at least 52 weeks) remission in 59 % patients vs. 42 % in pacients with placebo and standard therapy.
-
18. 04. 2017
MSCs for HBV-Related Acute-on-Chronic Liver Failure
-
10. 04. 2017
Stem cells used to treat erectile dysfunction
-
03. 04. 2017
Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia
-
27. 03. 2017
Mesenchymal stem cells in a murine ovalbumin asthma model
-
20. 03. 2017
Mesenchymal stem cells for lung melanoma metastases therapy